Qilu Pharmaceutical Presents P-II Study Results of QL1706 for the Treatment of Non-Small Cell Lung Cancer at ESMO 2022
Shots:
- The P-II study evaluating QL1706 + CT and bevacizumab in 100 patients with stage IIIB/C & stage IV with wild-type & mutated EGFR
- Among 29 & 31 patients treated with QL1706 (5mg/kg, q3w) + CT with wild-type EGFR & with mutated EGFR for 2 & 4 cycles and then QL1706 (5mg/kg, q2w) for maintenance therapy until disease progression or other discontinuation events showed the median follow-up was 9.17mos. & 5.75mos., ORR was 58.6% (70.6% in sq. NSCLC cohort; 41.7% in non-sq. cohort) & 64.5%; DCR (93.1% & 93.5%), respectively
- m-PFS was 6.97mos. in patients with wild-type EGFR while PFS was not yet mature & 6mos. PFS rate was 61.3% in mutated EGFR, AEs were manageable & the safety profile was consistent with that reported for CT or anti-PD-1 & anti-CTLA-4 therapy
Ref: PRNewswire | Image: Qilu Pharmaceutical
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
